Fractyl Health, Inc. Common Stock

of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities E

Other Events. On January 29, 2026, the Company reported 6-month data from its REMAIN-1 Midpoint Cohort, a blinded, sham-controlled study evaluating Revita ® for

Financial Statements and Exhibits. Exhibit No Description 99.1 Press Release dated January 29, 2026 99.2 Conference Call Presentation dated January 29, 2026 104